Gloria Ying's subsidiary plans to acquire medical Puconoduo pharmaceutical company to announce Q3 financial report

On the 24th, Laimei Pharmaceuticals issued an announcement stating that the company’s joint venture, Aglaea and AglaeaPharma, signed the "Project Cooperation and Development Agreement" on October 22
.
Aglaea directly pays RMB 25 million in technical service fees to the qualified CRO jointly entrusted by both parties to the agreement, and AglaeaPharma provides the CRO with necessary information and material support for technical services, and jointly accelerates the progress of research and development projects
.
Aglaiya will obtain the preclinical results of four projects including AG56103-opioid receptor OPRM1 small molecule inhibitor, AG56196-BCAT1 small molecule inhibitor, AG56153-BRD4 PROTAC degrader and AG56251-AKT molecular glue degrader.
Exclusive licensing rights and sub-licensing rights for the resulting patent series in Greater China
.
(a)

Qizheng Tibetan Medicine: A net loss of 341 million yuan in the third quarter turned from profit to loss

On the 25th, Qizheng Tibetan Medicine issued an announcement stating that the operating income in the first three quarters was 1.
189 billion yuan, a year-on-year increase of 16.
37%; the net profit was 647 million yuan, a year-on-year increase of 99.
81%
.
The net loss in the third quarter was 341 million yuan, and the net profit in the same period last year was 103 million yuan, which turned from profit to loss
.
(a)

Harbin Pharmaceutical: Net profit of 487 million yuan in the first three quarters turned losses into profits

On the 25th, Harbin Pharmaceuticals issued an announcement stating that the operating income of the first three quarters was 9.
739 billion yuan, a year-on-year increase of 27.
33%; the net profit was 487 million yuan, and the net loss in the same period last year was 373 million yuan, turning losses into profits
.
Net profit in the third quarter was 144 million yuan, turning losses into profits
.
(a)

Antu Biology: Net profit of 304 million yuan in the third quarter increased by 26.
45% year-on-year

On the 25th, Antu Biological released an announcement stating that the operating income in the first three quarters was 2.
695 billion yuan, a year-on-year increase of 31.
64%; the net profit was 717 million yuan, a year-on-year increase of 39.
33%
.
Net profit in the third quarter was 304 million yuan, a year-on-year increase of 26.
45%
.
(a)

Guangzheng Ophthalmology: Net loss of 15.
29 million yuan in the third quarter turned from profit to loss

On the 24th, Guangzheng Ophthalmology issued an announcement stating that the operating income of the first three quarters was 779 million yuan, a year-on-year increase of 25.
96%; the net profit was 45.
997 million yuan, a year-on-year increase of 51.
74%
.
In the third quarter, the net loss was 15.
29 million yuan, which turned from profit to loss year-on-year
.
(a)

Tiankang Bio: The third quarter net loss of 434 million yuan turned from profit to loss

On the 24th, Tiankang Biological released an announcement stating that the company's operating income in the third quarter of 2021 was 4.
412 billion yuan, a year-on-year increase of 43.
01%; a net loss of 434 million yuan, a profit of 644 million yuan in the same period last year, a year-on-year turnaround
.
The company's net loss in the first three quarters was 193 million yuan, a year-on-year turnaround
.
(a)

Jinyu Medical: Net profit of 1.
672 billion yuan in the first three quarters increased by 58.
52% year-on-year

On the 25th, Golden Mile Medical issued an announcement stating that the operating income in the first three quarters was 8.
617 billion yuan, a year-on-year increase of 47.
87%; net profit was 1.
672 billion yuan, a year-on-year increase of 58.
52%
.
Net profit in the third quarter was 613 million yuan, a year-on-year increase of 22.
84%
.
(a)

Jiudian Pharmaceutical: Net profit of 169 million yuan in the first three quarters increased by 206.
62% year-on-year

On the 25th, Jiudian Pharmaceutical issued an announcement stating that the operating income of the first three quarters was 1.
13 billion yuan, a year-on-year increase of 71.
98%; the net profit was 169 million yuan, a year-on-year increase of 206.
62%
.
The net profit in the third quarter was 56.
4 million yuan, a year-on-year increase of 152.
17%
.
(a)

  Aier Ophthalmology: Net profit of 2.
003 billion yuan in the first three quarters increased by 29.
59% year-on-year

On the 25th, Aier Ophthalmology issued an announcement stating that the operating income in the first three quarters was 11.
596 billion yuan, a year-on-year increase of 35.
38%; the net profit was 2.
003 billion yuan, a year-on-year increase of 29.
59%
.
Net profit in the third quarter was 888 million yuan, a year-on-year increase of 2.
05%
.
(a)

   Genetron Health and Fosun Pharma reached an exclusive commercial cooperation on Seq-MRD®

Recently, Genetron Health announced the signing of an exclusive commercialization cooperation agreement with Jiangsu Fosun Pharmaceutical, a subsidiary of Shanghai Fosun Pharmaceutical Holdings, on Genetron Health's Seq-MRD® testing service
.
According to the agreement, Genetron Health and Jiangsu Fosun Pharma will jointly sell and jointly promote Seq-MRD® in key hospitals and clinics for hematological diseases in designated areas in China to serve acute lymphoblastic leukemia, multiple myeloma, and chronic lymphocytic leukemia Waiting for patients with lymphatic hematological tumors
.
(PR Newswire)

 Kangchen Pharmaceutical Appoints Sun Yuping as Secretary of the Board of Directors

On the 25th, Kangchen Pharmaceutical issued an announcement stating that the company agreed to appoint Sun Yuping as secretary of the company's board of directors for a term from the date of approval by the board of directors to the expiration of the third term of the board of directors
.
(a)

SINBON Pharmaceuticals Securities Affairs Representative Lin Hanlin resigns

On the 25th, SINBON Pharmaceuticals issued an announcement stating that Lin Hanlin had applied for resignation as a representative of securities affairs due to job adjustments.
The resignation report became effective from the date of delivery to the board of directors
.
After resigning as the representative of securities affairs, Lin Hanlin is still working in the company
.
(a)

Part3 Medicine News

Significantly improve the symptoms of adolescent eczema IL-13 monoclonal antibody reaches the phase 3 clinical endpoint

A few days ago, LEO Pharma announced that the fully humanized IL-13 monoclonal antibody tralokinumab has obtained positive results in a phase 3 clinical trial for the treatment of atopic dermatitis in adolescent patients
.
Compared with placebo, both doses of tralokinumab significantly improved the patient's efficacy indicators, and the drug was well tolerated
.
At week 16, the trial reached its primary and secondary endpoints.
Compared with placebo, more patients treated with tralokinumab achieved a clinical response, defined as meeting IGA 0/1 and/or EASI 75 criteria
.
According to IGA measurements, 21.
4% of patients in the 150 mg tralokinumab group and 17.
5% of the 300 mg tralokinumab group achieved smooth or almost smooth skin, compared with 4.
3% in the placebo group
.
According to the EASI measurement results, 28.
6% of the 150 mg tralokinumab group and 27.
8% of the 300 mg tralokinumab group had 75% or more improvement in pruritus from baseline, compared with 6.
4% in the placebo group
.
In terms of safety, the overall frequency and severity of adverse events in the trials between treatment groups were comparable; most adverse events were mild or moderate in severity
.
(WuXi AppTec)

 The Phase III study of Novartis Cananumumab for NSCLC failed

Novartis announced on the 25th that the phase III clinical study of IL-1β inhibitor Canakinumab combined with pembrolizumab plus platinum-based dual-drug chemotherapy did not reach the primary endpoint of improving overall survival and progression-free survival.
The indication is local first-line treatment.
Advanced or metastatic non-small cell lung cancer
.
(Medical Rubik's Cube)

   Sichuan Meidakang Huakang Pharmaceutical's Lenalidomide Capsules are accepted for production of imitation 4 types

A few days ago, the official website of CDE showed that lenalidomide capsules produced by Sichuan Meidakang Huakang Pharmaceutical Co.
, Ltd.
have been accepted for production of imitation 4 types
.
Lenalidomide is a synthetic glutamate derivative, which has the effect of inhibiting angiogenesis and immune regulation
.
(CDE)

Heyu Pharmaceutical's FGFR2/3 selective inhibitor is clinically approved in the U.
S.

On the 25th, Heyu Medicine announced that its oral FGFR2/3 highly selective inhibitor ABSK061 has been approved by the FDA for clinical research and will soon launch the first phase 1 human clinical trial for solid tumors
.
(Medicine Guanlan)

Zejing Pharmaceutical's application for clinical trial of ZG005 powder injection was accepted

On the 25th, Zejing Pharmaceutical issued an announcement stating that its clinical trial application for ZG005 powder injection was accepted by NMPA for the treatment of solid tumors
.
(a)

  Ganli Pharmaceutical's long-acting GLP-1 receptor agonist was approved for clinical use

According to CDE's latest announcement, Ganli Pharmaceutical's innovative therapeutic biological product GZR18 has obtained a number of clinical trials implied approval, and it is planned to be developed for obesity or overweight and type 2 diabetes
.
Public information shows that GZR18 is a glucagon-like peptide 1 receptor agonist drug, which is planned to be injected once a week
.
(CDE)

  Hengrui Medicine SHR-A1921 was approved for clinical use

On the 25th, the CDE official website showed that Hengrui Medicine's SHR-A1921 clinical trial application was approved by NMPA for the treatment of advanced malignant solid tumors
.
(CDE)

If this article violates your rights, please contact us
.